On the cutting edge of proprotein convertase pharmacology: From molecular concepts to clinical applications

Biomolecular Concepts

Volumn 2, Issue 5, 2011, Pages 421-438

  Couture, Frédéric ^a   DAnjou, Francois ^a   Day, Robert ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

drug design; inhibitors; peptides as drugs; peptidomimetics; proprotein convertases; therapeutic applications; translational medicine

Indexed keywords

MUS;

EID: 84860380797     PISSN: 18685021     EISSN: 1868503X     Source Type: Journal    
DOI: 10.1515/BMC.2011.034     Document Type: Review

References (115)

1. Fugére M, Day, R. Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 2005; 26: 294-301.
2. Hosaka M, Nagahama M, Kim WS, Watanabe T, Hatsuzawa K, Ikemizu J, Murakami K, Nakayama K. Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway. J Biol Chem 1991; 266: 12127-30.
3. Pasquato A, Pullikotil P, Asselin MC, Vacatello M, Paolillo L, Ghezzo F, Basso F, Di Bello C, Dettin M, Seidah NG. The proprotein convertase SKI-1/S1P In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J Biol Chem 2006; 281: 23471-81.
4. Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 2007; 85: 685-96.
5. Seidah NG, Chrétien M. Interactive report Proprotein and prohormone convertases: a family of subtilases generating dive rse bioactive polypeptides 1. Brain Res 1999; 848: 45-62.
6. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, Hutton JC, ORahilly S. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997; 16: 303-6.
7. Taylor NA, Van De Ven WJM, Creemers JWM. Curbing activation: proprotein convertases in homeostasis and pathology. FASEB J 2003; 17: 1215-27.
8. Bergeron F, Leduc R, Day R, et al. Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J Mol Endocrinol 2000; 24: 1-22.
9. Nour N, Mort JS, Salvas A, Mbikay M, Morrison CJ, Overall CM, Seidah NG. The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases. Mol Biol Cell 2005; 16: 5215-26.
10. Henrich S, Lindberg I, Bode W, Than ME. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol 2005; 345: 211-27.
11. De Bie I, Marcinkiewicz M, Malide D, Lazure C, Nakayama K, Bendayan M, Seidah NG. The isoforms of proprotein convertase PC5 are sorted to different subcellular compartments. J Cell Biol 1996; 135: 1261-75.
12. Essalmani R, Marcinkiewicz J, Chamberland A, Mbikay M, Chrétien M, Seidah NG, Prat A. Deletion of the gene encoding proprotein convertase 5 / 6 causes early embryonic lethality in the mouse Mol Cell Biol 2006; 26: 354-61.
13. Arolas JL, Vendrell J, Aviles FX, Fricker LD. Metallocarboxypeptidases: emerging drug targets in biomedicine Curr Pharm Des 2007: 13: 349-66.
14. Maeda Y, Kinoshita T. The acidic environment of the golgi is critical for glycosylation and transport. Methods Enzymol 2010; 480: 495-510.
15. Duckert P, Brunak S, Blom N. Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 2004; 17; 107-12.
16. Remacle AG, Shiryaev SA, Oh E-S, Cieplak P, Srinivasan A, Wei G, Liddington RC, Ratnikov BI, Parent A, Desjardins R, Day R, Smith JW, Lebl M, Strongin AY. Substrate cleavage analysis of furin and related proprotein convertases. A comparative study. J Biol Chem 2008; 283: 20897-906.
17. Tian S, Huang Q, Fang Y, Wu J. Furin DB: a database of 20-residue furin cleavage site motifs, substrates and their associated drugs. Int J Mol Sci 2011; 12: 1060-5.
18. Garten W, Hans-Dieter K. Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. Trends Microbiol 2008; 27: 156-67.
19. Urata S, Yun N, Pasquato A, Paessler S, Kunz S, de la Torre JC. Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol 2011; 85: 795-803.
20. Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992; 360: 358-61.
21. Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, Thomas G, Chrétien M, Seidah NG. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem J 1996; 314: 521-32.
22. Xiao Y, Chen G, Richard J, Rougeau N, Li H, Seidah NG, Cohen EA. Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology 2008; 372: 384-97.
23. Guo X-L, Li L, Wei D-Q, Zhu Y-S, Chou K-C. Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin. Amino Acids 2008; 35: 375-82.
24. Richards RM, Lowy DR, Schiller JT, Day PM. Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc Natl Acad Sci USA 2006; 103: 1522-7.
25. Zhang X, Fugére M, Day R, Kielian M. Furin processing and proteolytic activation of semliki forest virus. J Virol 2003; 77: 2981-9.
26. Ozden S, Lucas-Hourani M, Ceccaldi P-E, Basak A, Valentine M, Benjannet S, Hamelin J, Jacob Y, Mamchaoui K, Mouly V, Després P, Gessain A, Butler-Browne G, Chrétien M, Tangy F, Vidalain PO, Seidah NG. Inhibition of Chikungunya virus infection in cultured human muscle cells by furin inhibitors: impairment of the maturation of the E2 surface glycoprotein. J Biol Chem 2008; 283: 21899-908.
27. Rojek JM, Pasqual G, Sanchez AB, Nguyen N-T, de la Torre J-C, Kunz S. Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J Virol 2010; 84: 573-84.
28. Creemers JW, Roebroek AJ, Van de Ven WJ. Expression in human lung tumor cells of the proprotein processing enzyme PC1/PC3 Cloning and primary sequence of a 5 kb cDNA. FEBS Lett 1992; 300: 82-8.
29. Clark D.A., Day R, Seidah N, Moody TW, Cuttitta F, Davis TP. Protease inhibitors suppress in vitro growth of human small cell lung cancer. Peptides 1993; 14: 1021-8.
30. Khatib A-M, Siegfried G, Chrétien M, Metrakos P, Seidah NG. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 2002; 160: 1921-35.
31. Bassi D.E., Cicco RLD, Cenna J, Litwin S, Cukierman E, Klein-Szanto AJP. PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res 2005; 65: 7310-9.
32. Mahloogi H, Bassi D.E., Klein-Szanto AJP. Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis 2002; 23: 565-72.
33. Bassi D.E., Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, and Klein-Szanto AJ. Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 2001; 31: 224-32.
34. Page RE, Klein-Szanto AJP, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ, Bassi D.E. Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 2007; 29: 289-99.
35. Cheng M, Watson PH, Paterson JA, Seidah N, Chrétien M, Shiu RP. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997; 71: 966-71.
36. Konoshita T, Gasc J, Villard E, Takeda R, Seidah N, Corvol P, Pinet F. Expression of PC2 and PC1/PC3 in human pheochromocytomas. Mol Cell Endocrinol 1994: 99: 307-14.
37. Jin L, Kulig E, Qian X, Scheithauer BW, Young WF, Davis DH, Seidah NG, Chrétien M, Lloyd RV. Distribution and regulation of proconvertases PC1 and PC2 in human pituitary adenomas. Pituitary 1999; 1: 187-95.
38. DAnjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Fournier I, Salzet M, Day R. Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol 2011; 4: 157-72.
39. Fu Y, Campbell EJ, Shepherd TG, Nachtigal MW. Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells. Mol Cancer Res 2003; 1: 569-76.
40. Sun X, Essalmani R, Seidah NG, Prat A. The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol Cancer 2009; 8: 73.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
42. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, Kundu GC. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 2006; 6: 819-30.
43. Kumar V, Behera R, Lohite K, Karnik S, Kundu GC. p38 kinase is crucial for osteopontin-induced furin expression that supports cervical cancer progression. Cancer Res 2010; 70: 10381-91.
44. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG, Khatib A-M. Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 2008; 118: 352-63.
45. Bassi D.E., Zhang J, Cenna J, Litwin S, Cukierman E, Kleinszanto AJP. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis. Neoplasia 2010; 12: 516-26.
46. Grushko G, Schneiderman R, Maroudas A. Some biochemical and biophysical parameters for the study of the pathogenesis of osteoarthritis: a comparison between the processes of ageing and degeneration in human hip cartilage. Conect Tissue Res 1989; 19: 149-76.
47. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma H-L, Flannery CR, Peluso D, Kanki K, Yang Z, Majumdar MK, Morris EA. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644-8.
48. Malfait M, Arner EC, Song RH, Alston JT, Markosyan S, Staten N, Yang Z, Griggs DW, Tortorella MD. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys 2008; 478: 43-51.
49. Byun S, Tortorella MD, Malfait A-M, Fok K, Frank EH, Grodzinsky AJ. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. Arch Biochem Biophys 2010; 499: 32-9.
50. Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol Chem 2006; 387: 871-7.
51. Davignon J, Dubuc G, Seidah NG. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010; 12: 308-15.
52. Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A, Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008; 283: 2363-72.
53. Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J. Molecular basis of LDL receptor recognition by PCSK9. Proc Natl Acad Sci USA 2008; 105: 1820-5.
54. Poirier S, Mayer G, Poupon V, Mcpherson PS, Desjardins R, Ly K, Asselin M-C, Day R, Duclos FJ, Witmer M, Parker R, Prat A, Seidah NG. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation. J Biol Chem 2009; 284: 28856-64.
55. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006; 281: 30561-72.
56. Abifadel M, Pakradouni J, Collin M, Samson-Bouma M-E, Varret M, Rabés J-P, Boileau C. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010; 20: 1547-71.
57. Sakai J, Rawson RB, Espenshade PJ, Cheng D, Seegmiller AC, Goldstein JL, Brown MS. Molecular identification of the sterolregulated luminal protease that cleaves S.R.EBPs and controls lipid composition of animal cells. Mol Cell Biol 1998; 2: 505-14.
58. Rawson RB. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 2003; 70: 221-31.
59. Stawowy P, Fleck E. Proprotein convertases furin and PC5: targeting atherosclerosis and restenosis at multiple levels. J Mol Med 2005; 83: 865-75.
60. Liu J, Afroza H, Rader DJ, Jin W. Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases. J Biol Chem 2010; 285: 27561-70.
61. Lei X, Shi F, Basu D, Huq A, Routhier S, Day R, Jin W. Proteolytic processing of angiopoietin-like protein 4 by proprotein convertases modulates its inhibitory effects on lipoprotein lipase activity. J Biol Chem 2011; 286: 15747-56.
62. Lah TT, Duran Alonso MB, Van Noorden CJ. Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 2006; 6: 257-79.
63. Vihinen P, Ala-aho R, Kähäri V-M. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203-20.
64. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000; 19: 6642-50.
65. Creemers JW, Khatib AM. Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci 2008; 172: 4960-71.
66. Scamuffa N, Calvo F, Chrétien M, Seidah NG, Khatib A-M. Proprotein convertases: lessons from knockouts. FASEB J 2006; 20: 1954-63.
67. Seidah NG. What lies ahead for the proprotein convertases? Ann NY Acad Sci 2011; 1220: 149-161.
68. Chitramuthu BP, Baranowski DC, Cadieux B, Rousselet E, Seidah NG, Bennett HPJ. Molecular cloning and embryonic expression of zebrafish PCSK5 co-orthologues: functional assessment during lateral line development. Dev Dyn 2010; 239: 2933-46.
69. Mesnard D, Constam DB. Imaging proprotein convertase activities and their regulation in the implanting mouse blastocyst. J Cell Biol 2010; 191: 129-39.
70. Roebroek AJ, Taylor NA, Louagie E, Pauli I, Smeijers L, Snellinx A, Lauwers A, Van de Ven WJ, Hartmann D, Creemers JW. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 2004; 279: 53442-50.
71. De Vos L, Declercq J, Rosas GG, Van Damme B, Roebroek A, Vermorken F, Ceuppens J, van de Ven W, Creemers J. MMTVcre- mediated fur inactivation concomitant with PLAG1 protooncogene activation delays salivary gland tumorigenesis in mice. Int J Oncol 2008; 32: 1073-83.
72. Pan H, Che F-Y, Peng B, Steiner DF, Pintar JE, Fricker LD. The role of prohormone convertase-2 in hypothalamic neuropeptide processing: a quantitative neuropeptidomic study. J Neurochem 2006; 98: 1763-77.
73. Wardman JH, Zhang X, Gagnon S, Castro LM, Zhu X, Steiner DF, Day R, Fricker LD. Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. J Neurochem 2010; 114: 215-25.
74. Funkelstein L, Beinfeld M, Minokadeh A, Zadina J, Hook V. Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides. Neuropeptides 2010; 44: 457-66.
75. Bonneterre J, Peyrat JP, Beuscart R, Dã A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 1990; 50: 6931-5.
76. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby A. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 1997; 183: 412-7.
77. Stawowy P, Kallisch H, Kilimnik A, Margeta C, Seidah NG, Chrétien M, Fleck E, Graf K. Proprotein convertases regulate insulin-like growth factor 1-induced membrane-type 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. Biochem Biophys Res Commun 2004; 321: 531-8.
78. Arsenault D, Lucien F, Dubois CM. Hypoxia enhances cancer cell invasion through relocalization of the proprotein convertase furin from the trans-Golgi network to the cell surface. J Cell Physiol 2011
79. Drag M, Salvesen GS. Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 2010; 9: 690-671.
80. Shiryaev SA, Remacle G, Ratnikov BI, Nelson NA, Savinov AY, Wei G, Bottini M, Rega MF, Parent A, Desjardins R, Fugere M, Day R, Sabet M, Pellecchia M, Liddington RC, Smith JW, Mustelin T, Guiney DG, Lebl M, Strongin AY. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem 2007; 282: 20847-53.
81. Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, Cieplak P, Millis SZ, Desjardins R, Routhier S, Yuan XW, Neugebauer WA, Day R, Strongin AY. Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. Int J Biochem Cell Biol 2010; 42: 987-95.
82. Cameron A, Appel J, Houghten RA, Lindberg I. Polyarginines are potent furin inhibitors. J Biol Chem 2000; 275: 36741-9.
83. Fugére M, Appel J, Houghten RA, Lindberg I, Day R. Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol Pharmacol 2007; 71: 323-32.
84. Karicherla P, Hobden JA. Nona-D-arginine therapy for Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2009; 50: 256-62.
85. Karicherla P, Hobden JA. Nona-D-arginine amide for prophylaxis and treatment of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 2010; 35: 220-4.
86. Hajdin K, DAlessandro V, Niggli FK, Schäfer BW, Bernasconi M. Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS One 2010; 5: e10445.
87. Angliker H, Wikstrom P, Shaw E, Brenner C, and Fuller RS. The synthesis of inhibitors for processing proteinases and their action on the Kex2 proteinase of yeast. Biochem J 1993; 293 (Pt 1): 75-81.
88. Jean F, Stella K, Thomas L, Liu G, Xiang Y, Reason AJ, Thomas G. alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic. Proc Natl Acad Sci USA 1998; 95: 7293-8.
89. Fugére M, Limperis PC, Beaulieu-Audy V, Gagnon F, Lavigne P, Klarskov K, Leduc R, Day R. Inhibitory potency and specificity of subtilase-like pro-protein convertase (SPC) prodomains. J Biol Chem 2002; 277: 7648-56.
90. Hay BA, Abrams B, Zumbrunn AY, Valentine JJ, Warren LC, Petras SF, Shelly LD, Xia A, Varghese AH, Hawkins JL, Van Campb JA, Robbinsa MD, Landschulza K, Harwood Jr HJ. Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg Med Chem Lett 2007; 17: 4411-4.
91. Hawkins JL, Robbins MD, Warren LC, Xia D, Petras SF, Valentine JJ, Varghese AH, Wang I-K, Subashi TA, Shelly LD, Hay BA, Landschulz KT, Geoghegan KF, Harwood HJ Jr. Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther 2008; 326: 801-8.
92. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-Darginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002; 70: 7136-9.
93. Chan JCY, Piper D.E., Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Dia Y, Shetterlya S, Arimuraa Z, Salomonisa H, Romanowb WG, Thibaultb ST, Zhange R, Caoe P, Yange X-P, Yue T, Lue M, Retterf MW, Kwonf G, Henneg K, Panc O, Tsaid M-M, Fuchslocherd B, Yangd E, Zhouh L, Leed KJ, Darisd M, Shengd J, Wange Y, Shene WD, Yeha W-C, Emeryf M, Walkerb NPC, Shana B, Schwarza M, Jacksona SM. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009; 106: 9820-5.
94. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, Butler D, Charisse K, Dorkin R, Fan Y, Gamba-Vitalo C, Hadwiger P, Jayaraman M, John M, Jayaprakash KN, Maier M, Nechev L, Rajeev KG, Read T, Röhl I, Soutschek J, Tan P, Wong J, Wang G, Zimmermann T, de Fougerolles A, Vornlocher H-P, Langer R, Anderson DG, Manoharan M, Koteliansky V, Horton JD, Fitzgerald K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-20.
95. Fugére M, Day, R. Inhibitors of the subtilase-like pro-protein convertases (SPCs). Curr Pharm Des 2002; 8: 549-62.
96. Chrétien M, Seidah NG, Basak A, Mbikay M. Proprotein convertases as therapeutic targets. Expert Opin Ther Targets 2008; 12: 1289-300.
97. Szymkowski D.E. Rational optimization of proteins as drugs: a new era of medicinal biology. Drug Discov Today 2004; 9: 381-3.
98. Stevenson CL. Advances in peptide pharmaceuticals. Curr Pharm Biotechnol 2009; 10: 122-37.
99. Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci 2010; 31: 434-41.
100. Pillarisetti S. Are peptides the future? Small molecule versus peptides. Curr Pharm Biotechnol 2006; 7: 225-7.
101. Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotechnol 2006; 7: 261-76.
102. Tian S, Jianhua W. Comparative study of the binding pockets of mammalian proprotein convertases and its implications for the design of specific small molecule inhibitors. Int J Biol Sci 2010; 6: 89-95.
103. Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, Lindberg I, Bode W, Than ME. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol 2003; 10: 520-6.
104. Basak A, Khatib A-M, Mohottalage D, Basak S, Kolajova M, Bag SS, Basak A. A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C PLoS One 4, e7700, 2009.
105. Basak A, Cooper S, Roberge AG, Banik UK, Chrétien M, Seidah NG. Andrographis paniculata and their succinoyl esters. Biochem J 1999; 338: 107-13.
106. Jiao G-S, Cregar L, Wang J, Millis SZ, Tang C, OMalley S, Johnson AT, Sareth S, Larson J, Thomas G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine. Proc Natl Acad Sci USA 2006; 103: 19707-12.
107. Komiyama T, Coppola JM, Larsen MJ, van Dort ME, Ross BD, Day R, Rehemtulla A, Fuller RS. Inhibition of furin/ proprotein convertase-catalyzed surface and intracellular processing by small molecules. J Biol Chem 2009; 284: 15729-38.
108. Kowalska D, Liu J, Appel J.R., Ozawa A, Nefzi A, Mackin B, Houghten RA, Lindberg I. Synthetic small-molecule prohormone convertase 2 inhibitors. Mol Pharmacol 2009; 75: 617-25.
109. Becker GL, Sielaff F, Than ME, Lindberg I, Routhier S, Day R, Lu Y, Garten W, Steinmetzer T. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010; 53: 1067-75.
110. Hummel G, Reineke U, Reimer U. Translating peptides into small molecules. Mol Biosyst 2006; 2: 499-508.
111. Podsiadlo P, Komiyama T, Fuller RS, Blum O. Furin inhibition by compounds of copper and zinc. J Biol Chem 2004; 279: 36219-27.
112. Coppola JM, Hamilton CA, Bhojani S, Larsen MJ, Ross BD, Rehemtulla A. Identification of inhibitors using a cell based assay for monitoring golgi-resident protease activity. Anal Biochem 2007; 364: 19-29.
113. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-74.
114. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77: 13-22.
115. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006; 13: 541-52.